Michael is a research associate in our Drug Discovery Program. He graduated from UCLA ('24) with a Molecular, Cell, and Developmental Biology BS and Biomedical Research minor. Currently, he is helping to develop next-generation potent and brain-penetrant tyrosine kinase inhibitors for glioblastoma (GBM). Specifically, he investigates DMPK aspects of these novel inhibitors including brain penetrance and drug exposure, protein binding, and tolerability. He is applying to medical schools in 2025.